Holen Sie sich die Stockscreener-App
16.30
3.16%
0.50
Schlusskurs vom Vortag:
$15.80
Offen:
$16.11
24-Stunden-Volumen:
26.07M
Relative Volume:
1.24
Marktkapitalisierung:
$3.71B
Einnahmen:
$1.78B
Nettoeinkommen (Verlust:
$164.40M
KGV:
23.62
EPS:
0.69
Netto-Cashflow:
$236.51M
1W Leistung:
-29.19%
1M Leistung:
-49.38%
6M Leistung:
-66.27%
1J Leistung:
-72.46%
1-Tages-Spanne:
$16.08
$16.87
1-Wochen-Bereich:
$15.63
$19.52
52-Wochen-Spanne:
$15.63
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
16.30 | 3.60B | 1.78B | 164.40M | 236.51M | 0.69 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.46 | 58.03B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.65 | 55.37B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.20 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.98 | 39.50B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
473.66 | 20.50B | 3.13B | 1.27B | 1.12B | 26.39 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
How Ozempic Brought a Napster Moment to Big Pharma - The Wall Street Journal
Hims & Hers Health, Inc. (NYSE:HIMS) Given Average Rating of "Hold" by Brokerages - MarketBeat
Hims & Hers Health (HIMS) Is Down 29.2% After Semaglutide Lawsuit And DOJ ReferralHas The Bull Case Changed? - Yahoo Finance
Hims & Hers Unveils New Health Offerings Amid Patent Disputes - timothysykes.com
Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know - The Globe and Mail
Hims & Hers Falls Over 50% as Novo Files Obesity Lawsuit - GuruFocus
Top 10 Most Shorted Stocks: CleanSpark, Hims & Hers And More - Benzinga
Hims & Hers Health (HIMS) Faces Legal and Market Challenges - GuruFocus
HIMS Stock Sees Bullish Options Activity with Earnings on the Ho - GuruFocus
Hims & Hers short interest climbs amid legal risk related to weight loss pill - Seeking Alpha
Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows - whbl.com
Exclusive: Before Hims’ GLP-1 pill fallout, its pharmacy partner was already drawing scrutiny from state regulators - Sherwood News
Hims & Hers Shorts Up $1.3 Billion This Year on Legal Risk - Bloomberg.com
Hims & Hers (HIMS) Faces High Short Interest Amid FDA Speculatio - GuruFocus
Most and least shorted mid-to mega-cap healthcare stocks in January - Seeking Alpha
Analysis-US could take action including fines against Hims after brief Wegovy copy launch - WKZO
HIMS Stock Falls -47% With A 10-day Losing Spree On FDA Crackdown - Trefis
Hims & Hers Health (NYSE:HIMS) Hits New 52-Week LowHere's Why - MarketBeat
Hims & Hers Strengthens Integrated Personalized Digital Care Platform - The Globe and Mail
Mixed options sentiment in Hims and Hers Health with shares down 2.18% - Yahoo Finance
Him & Hers Health Stock Forecast 2026–2030 | Future Outlook - Capital.com
Novo Nordisk CEO Sees Opportunity For 15 Million New Patients As Medicare Covers Obesity Drugs - Benzinga
Hims & Hers Pulls Wegovy Pill Dupe After FDA Threats — Novo Nordisk Files Patent Lawsuit Anyway - Everyday Health
Novo to Follow Lilly and Sell Obesity Shot Wegovy in Vials - Bloomberg.com
Hims & Hers Faces Legal and Regulatory Headwinds, Stock Plummets - StocksToTrade
HIMS Stock Plunges 8 Straight Days: Is The GLP-1 Fallout Already Priced In? - Stocktwits
HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell? - The Globe and Mail
Hims & Hers: Does Big Pharma Always Win? (Rating Downgrade) (NYSE:HIMS) - Seeking Alpha
HIMS Selloff Creates De-Risked Entry (NYSE:HIMS) - Seeking Alpha
Hims & Hers Halts Compounded Semaglutide Pill Offering After FDA's Crackdown Warning - AOL.com
Pharmaceutical industry spends more on ads in the US despite stricter FDA guidelines - medwatch.com
The Price Is Right For Hims & Hers Health, Inc. (NYSE:HIMS) Even After Diving 46% - simplywall.st
Novo’s GLP-1 Patent Suit Against Hims Takes Aim at Compounding - Bloomberg Law News
Hims is in the crosshairs. Is a crackdown coming for compounding? - statnews.com
Deutsche Bank Maintains Hold on HIMS (Hims & Hers) Feb 10, 2026 - Meyka
'Health risk': Novo Nordisk sues Hims & Hers over cheaper version of Ozempic, Wegovy fat loss pills - MSN
Meet The Attys For Novo Nordisk In Hims & Hers GLP-1 Row - Law360
Legal pressures mount for Hims & Hers over GLP-1 sales - The Hill
Novo Nordisk Takes On Hims Over Copycat GLP-1 Pill - Law360
Stocks making big moves yesterday: Shopify, Snowflake, Ryan Specialty, Merchants Bancorp, and Hims & Hers Health - The Globe and Mail
Novo Nordisk Files Patent Lawsuit Against Hims & Hers Over Compounded Semaglutide Products - Law Commentary
Hims & Hers Health (NYSE:HIMS) Shares Down 6% Following Analyst Downgrade - MarketBeat
Fight over GLP-1 alternatives escalates as Novo Nordisk sues Hims & Hers - Axios
Novo Nordisk sues Hims & Hers over ‘knock-off Wegovy’ - The Hill
Decoding Hims & Hers Health's Options Activity: What's the Big Picture? - Benzinga
Palmetto Grain Brokerage - Palmetto Grain Brokerage
As Hims & Hers Gets Hit With Major Wegovy Loss, Should You Buy the Dip in Deeply Oversold HIMS Stock? - Barchart.com
Hims & Hers Health: The GLP-1 Trade Just Got Real (Rating Downgrade) (NYSE:HIMS) - Seeking Alpha
The Vertical Integration of Wellness: A Deep Dive into Hims & Hers Health (HIMS) - FinancialContent
Deutsche Bank Cuts Price Target on Hims & Hers Health to $31 From $42, Keeps Hold Rating - marketscreener.com
Hims & Hers Health Stock (HIMS) Opinions on Novo Nordisk Lawsuit - Quiver Quantitative
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.19%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):